Navigation Links
'Stereo' Mammography Takes Breast Imaging to a New Dimension
Date:11/28/2007

CHICAGO, Nov. 28 /PRNewswire/ -- Stereoscopic digital mammography, a new diagnostic technique capable of producing three-dimensional, in-depth views of breast tissue, could significantly reduce the number of women who are recalled for additional tests following routine screening mammography. Results of a clinical trial being conducted at Emory University Breast Clinic in Atlanta were presented today at the annual meeting of the Radiological Society of North America (RSNA).

"Standard mammography is one of the most difficult radiographic exams to interpret," said David J. Getty, Ph.D., division scientist at BBN Technologies of Cambridge, Mass. "In a two-dimensional image of the breast, subtle lesions may be masked by underlying or overlying normal tissue and thus be missed, and normal tissue scattered at different depths can align to mimic a lesion, leading to false-positive detections."

Stereoscopic digital mammography consists of two digital x-ray images of the breast acquired from two different points of view separated by about eight degrees. When the images are viewed on a stereo display workstation, the radiologist is able to see the internal structure of the breast in three dimensions. In the ongoing clinical trial, researchers use a full-field digital mammography unit modified to take stereo pairs of images. The workstation enables the mammographer to fuse the stereo image pair and to view the breast in depth.

"Stereo viewing is the only way to see the structure within the breast volume in true depth," said Dr. Getty, who has been working on the development of the technology over the past 12 years.

As of July 2007, 1,093 patients at elevated risk for developing breast cancer were enrolled in the trial. Each patient received a full-field, standard digital mammography screening examination and a full-field, stereoscopic digital exam, which were then read independently by different radiologists.

A total of 259 suspicious findings were detected by the combined mammography procedures and were referred for additional diagnostic testing, including biopsy when indicated. Of those, 109 were determined to be true lesions. Standard mammography missed 40 of the 109 lesions while the stereoscopic exam failed to detect 24.

"Our early results suggest that stereo digital mammography could contribute to the earlier detection of cancer," Dr. Getty said. "A small percentage of the additional lesions missed by standard mammography but detected by stereoscopic mammography will turn out to be cancerous."

Of the 259 findings, 150 were false positives, meaning further testing revealed that no abnormality was present. Standard mammography yielded 103 false positives; stereo mammography yielded 53.

"In our study, stereo digital mammography reduced false positives by 49 percent," said Dr. Getty. "This could have a significant impact by cutting in half the number of women who are needlessly recalled for additional diagnostic work-ups, resulting in a large savings in cost and patient anxiety."

By the end of the clinical trial this December, a total of 1,500 women at elevated risk of developing breast cancer will have received both the stereo and standard digital mammography screening exams.

According to Dr. Getty, offering wide-scale stereoscopic digital mammography would entail minor changes to digital mammography equipment and software.

Co-authors of the paper are C.J. D'Orsi, M.D., R.M. Pickett, Ph.D., M.S. Newell, M.D., K.R. Gundry, M.D., S.F. Roberson, M.D., S.R. Bates, M.D., et al.

Dr. Getty is employed by BBN Technologies. BBN Technologies and Planar Systems developed the stereo display workstation used in the trial.

AT A GLANCE

-- A new mammography technology allows radiologists to detect more cancers

with fewer false positives.

-- Stereoscopic digital mammography produces three-dimensional, in-depth

views of breast tissue.

-- In a clinical trial of 1,093 women, stereoscopic digital mammography

detected more true lesions than standard digital mammography and

reduced false-positive findings by nearly half.

Note: Copies of RSNA 2007 news releases and electronic images will be available online at RSNA.org/press07 beginning Monday, Nov. 26.

RSNA is an association of more than 41,000 radiologists, radiation oncologists, medical physicists and related scientists committed to excellence in patient care through education and research. The Society is based in Oak Brook, Ill. (RSNA.org)

Editor's note: The data in these releases may differ from those in the printed abstract and those actually presented at the meeting, as researchers continue to update their data right up until the meeting. To ensure you are using the most up-to-date information, please call the RSNA Newsroom at 1-312-949-3233.


'/>"/>
SOURCE Radiological Society of North America
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. BSGI Posts Higher Sensitivity than Mammography or MRI for the Detection of Ductal Carcinoma In Situ
2. VA National Campaign Takes Aim at Resistant Staph Infections
3. Study Confirms That New Protocol Shortens the Time It Takes to Open Blocked Arteries for Heart Attack Patients
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
6. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
7. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
8. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
9. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
10. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
11. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016 KEY FINDINGS North ... the market in 2016 and is expected to continue ... to a large number of surgical procedures that are ... share in the patient temperature management market.) Patient warming ... loss of blood during surgeries, lowering the risks of ...
(Date:12/8/2016)... , Dec 8, 2016 Research and Markets has announced ... report to their offering. ... This report analyzes the worldwide markets for Endodontic Supplies ... Canada , Japan , Europe ... Rest of World. Annual estimates and forecasts are provided for the ...
(Date:12/8/2016)... 8, 2016 Bodycad announced it has ... the accuracy, reproducibility and speed for 3D constructs ... small bone orthopaedic applications. These patents are critical ... orthopaedic restorations based on each patient,s distinct anatomy. ... company harnesses the world,s first suite of orthopaedic ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... ... Premier Fitness Camp (PFC) and The Chopra Center for Wellbeing announced today ... at their world headquarters of Omni La Costa Resort & Spa in San Diego. ... weight loss, personal development, a healthy lifestyle, or mental and physical healing. The week-long ...
(Date:12/8/2016)... Somerset, N.J. (PRWEB) , ... December 08, 2016 ... ... advanced delivery technologies and development solutions for drugs, biologics and consumer health products, ... The PSCI was set up in 2006 as a non-profit organization to unite ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... California Senate ... medical payments per workers’ compensation claim in 2013 and 2014, according to CompScope™ ... Research Institute (WCRI) . , According to the study, medical payments per claim in ...
(Date:12/8/2016)... ... December 08, 2016 , ... Vida Health, the digital health platform ... by Canvas Ventures . Other investors include Nokia Growth Partners (NGP) and returning ... serve more consumers who are managing chronic conditions or simply want to ...
(Date:12/8/2016)... ... 08, 2016 , ... The Dan Carlisle Agency, an Alabama-owned ... is announcing the launch of a charity drive to raise support and awareness ... and children in Birmingham has grown steadily since the 1980’s, and the Pathways ...
Breaking Medicine News(10 mins):